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Abstract 
Background: Demineralized dentin matrix (DDM) is commonly used as a bone-graft substitute. This study measured 
and compared human hepatitis B viruses (HBV) DNA in fresh dentin to that of dentin processed into DDM extracted 
during dental treatment from HBV-infected patients. The hypothesis was that the processing procedure for DDM 
would inactivate or eliminate HBV in the dentin matrix obtained from infected patients.
Methods: Dentin from eighteen HBV-infected patients was collected and each dentin specimen was divided 
into two fragments. One fragment was used before processing as fresh dentin (control group) and the other was 
processed into DDM (experimental group). DNA was extracted and purified from each fresh and processed dentin 
specimen and the HBV DNA copy number quantitated by real time polymerase chain reaction. The HBV DNA copy 
number in the fresh dentin specimens were compared relative to serologic test results. The second parameter was to 
evaluate the effectiveness of the processing procedure (defatting, demineralization, freeze-drying, and sterilization) 
to inactivate or eliminate HBV by comparing the DNA copy number in the processed DDM with that in the matched 
fresh dentin specimens. All results were analyzed using Mann–Whitney U test to compare numerical measurements 
between groups and differences were considered statistically significant at P-values less than 0.05.
Results: The presence of HBV DNA was detected in 55.56% (10/18) of the fresh dentin specimens. For the ten HBV 
DNA-positive fresh dentin specimens, HBV DNA was detected in two (20%) of the matched processed dentin speci-
mens. The copy number of HBV DNA in the two positive processed dentin specimens was 1.79 and 4.03, which were 
statistically lower than that of the fresh dentin specimens (P = 0.0167).
Conclusions: The results from this study suggested that fresh dentin may be a carrier of HBV and that the procedure 
used to generate DDM extensively reduced the levels of HBV DNA. Further studies are needed to evaluate the infec-
tivity of HBV in processed dentin.
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Background
Demineralized dentin matrix  (DDM) is one of the most 
acid-insoluble collagenous scaffolds containing  minerals 
and noncollagenous proteins (NCPs) such as bone mor-
phogenetic protein (BMP) and is now commonly used as 
a bone-graft substitute. Experimental and clinical studies 
have clearly documented the osteoinductive properties of 
DDM and its value as an alternative to autogenous bone 
graft [1, 2]. In addition to the development of autog-
enous DDM, several in  vivo experimental studies on 
allogenic DDM have been performed and showed prom-
ising results for bone repair without any immunologic 
responses hindering the osteoinductive and osteocon-
ductive capacities of DDM. Subsequently, several clini-
cal studies have been conducted to evaluate the clinical 
efficacy and safety of allogenic DDM between biological 
family members [3, 4].
However, in addition to the biologic aspects of allogenic 
DDM applications, the single largest potential disadvan-
tage might be the risk of transmission of viral disease as 
has been seen throughout the developmental history of 
Bone Bank [5, 6].  Even though the biologic use of allo-
genic DDM has been supported by several experimental 
and clinical studies, certain viral diseases, such as those 
caused by human immunodeficiency virus (HIV) and 
hepatitis B and C viruses may be transmitted through the 
implantation of human dentin-based products derived 
from infected donors.
The processing of bone to produce demineralized bone 
matrix (DBM) entails conditions harsh enough to achieve 
significant levels of viral inactivation. This allows the 
pooling process of samples to enhance product quality 
and effectiveness without increasing, and perhaps even 
decreasing, the risk of viral transmission [7]. For using 
DDM as an allogenic bone-graft substitute, the risk of 
viral-disease transmission should be reduced or elimi-
nated. The processing procedure for producing DDM 
includes washing, defatting, demineralization, freeze-
drying, and sterilization, which removes unwanted mate-
rials from the extracted tooth, such as fat, antigens, and 
inactivated pathogens, while preserving the valuable 
minerals, collagen matrix, and non-collagenous proteins 
leading to rapid bone regeneration and bone remodeling 
[8].
An issue for using DDM as an allogenic bone-graft 
substitute is whether the allogenic dentin from infected 
patients could be a carrier for transmissible viral dis-
eases and if there is a potential risk of viral transmission, 
would the processing procedure reduce or eliminate the 
risk of transmission. In the current study, hepatitis B 
virus (HBV) was chosen as the target virus since it is the 
most prevalent viral infection in the Korean population 
at 3.7%, is present in saliva, semen, vaginal secretions 
and serum of infected patients, and since even with 
careful donor-screening and testing procedures in den-
tal clinics, it is still impossible to be completely sure 
that an extracted tooth is free of viral contamination [9, 
10]. This study was aimed at evaluating viral inactiva-
tion by the procedure used to process DDM by measur-
ing HBV DNA in dentin isolated from infected patients 
both before and after processing. The hypothesis was 
that dentin obtained from HBV-infected patients could 
be a carrier of viable HBV to graft recipients through 
the transplantation and that the processing procedure to 
generate DDM could completely inactivate or eliminate 
any HBV present in the dentin matrix.
Methods
Tooth collection from HBV‑infected patients
This study was approved by the Seoul National University 
Dental Hospital Institutional Review Board (SNUDH IRB 
No. CRI17011) and the Seoul National University Bun-
dang Hospital IRB (SNUBH IRB No. B-1705/395-308). 
All participants signed an informed consent agreement.
Eighteen  teeth from individuals chronically infected 
with HBV were extracted for clinical reasons during den-
tal treatment at SNUDH and SNUBH. The HBV infec-
tions were confirmed by serological tests with titers over 
1000 international units (IU)/mL (Table  1). All patients 
were negative for anti-hepatitis C virus (HCV) and anti-
HIV antibodies, which allowed for focusing on the hepa-
titis B virus surface antigen (HBsAg). Vertically infected 
infants and child patients were excluded. The teeth from 
the 18 HBV-infected  patients  were extracted, placed in 
sterile bottles, and stored in a refrigerator at the den-
tal clinic. The teeth were then aseptically  packaged and 
shipped on dry ice to the Korea Tooth Bank (KTB, Seoul, 
Korea). Upon arrival at KTB, each tooth was placed in 
new sterile bottles and stored at − 20  °C until further 
processing to prevent degradation of the HBV DNA.
Experimental design
The dentin obtained from the HBV-infected patients was 
divided into two pieces. One piece was used for HBV 
DNA measurement in fresh dentin (control group) and 
the second piece was processed for production of DDM 
(processed dentin) and then analyzed for HBV DNA. The 
comparison of HBV DNA levels in the fresh dentin com-
pared with that in the processed dentin was intended to 
evaluate the effectiveness of the processing procedure to 
inactivate or eliminate HBV in dentin (Fig. 1).
Preparation of fresh dentin and processed dentin
Each tooth was cleaned of all soft tissues, cavities, cal-
culus, restoration, and root canal materials using a den-
tal high-speed bur (FG 6856 018 Diamond Bur; Gebr. 
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Brasseler GmbH & Co, Lemgo, Germany) and washed by 
saline irrigation. The enamel portion over the cemento-
enamel-junctions was severed using a FG700 010 Cutting 
Bur. Root cementum was removed by scraping the sur-
face using #15 surgical blade and FG 6856018 Diamond 
Bur. The remaining root portion was divided into two 
pieces using a dental cutting bur (FG700 010 Cutting Bur; 
Gebr. Brasseler GmbH & Co). All dental pulp, soft tis-
sues, and attached hard tissues on the internal and exter-
nal surfaces were cleaned using a dental handpiece.
The pieces used as fresh dentin for measuring the level 
HBV DNA were washed three times with sterilized water 
and then dried  in a chamber at 56  °C  for 2  h (Fig.  1a). 
The other pieces were processed to DDM  particles as 
autogenous tooth bone graft material (AutoBT) accord-
ing to the previous report by the Korea Tooth Bank [8]. 
Briefly, the dentin  segments were ground and sieved to 
yield particles of 300 to 800 μm in size, washed, defatted, 
demineralized, freeze dried, and sterilized, all under tem-
perature-controlled sonication (40 kHz) and stirring. The 
particles were soaked in hydrogen peroxide  (H2O2) solu-
tion for 30 min and then washed repeatedly with distilled 
water. The particles were then immersed in 70% ethyl 
alcohol for 1 h. The defatted powders were washed three 
times with sterile distilled water for 10 min to remove the 
chemicals used in the processing. The particulate den-
tin was demineralized to 10 to 30% residual calcium (by 
weight) using 0.6  N HCl solution at room temperature 
for 3 min. The demineralized dentin particles were then 
washed three times for 10 min with sterile distilled water 
and a sodium phosphate buffer to remove residual acid. 
Next, the demineralized dentin  particles  were  soaked 
in 70%  ethanol and  H2O2 for 30  min at room tempera-
ture and then rinsed with sterile distilled water. The parti-
cles were freeze-dried over night to less than 5% residual 
moisture (by volume). The particles were packaged and 
finally sterilized with ethylene oxide gas (Fig. 1b).
HBV DNA measurements
DNA isolation and purification
In preparation for analysis by quantitative polymer-
ase chain reaction, individual samples of fresh and 
processed dentin (0.5  g) were decalcified  and digested 
using a Tbone EX Kit (DNA Chip Research Inc., Tokyo, 
Japan) followed by phenol–chloroform extraction. 
Total DNA was extracted according to the manufac-
turer’s instructions. Briefly, the dentin samples  were 
placed in 50-mL tubes containing 30  mL Solution A 
and soaked at 23  °C for 12  h. We then added 1.8  mL 
Solution B to each tube containing Solution A and the 
Table 1 Demographic information and  serological status of  the  patients from  whom the  teeth used in  the  study were 
collected
Eighteen teeth were obtained from patients infected with HBV. All patients were previously diagnosed as being chronically infected with HBsAg titers > 1000 IU/mL. 
The age range was from 29 to 79 years
HBV, hepatitis B virus; F, female; M, male; HBsAg, hepatitis B surface antigen; anti-HBs, antiviral antibody titer; IU, International Unit
Patient no. Sex/age Tooth number HBV examination date Tooth extraction date HBV examination
Serology (HBsAg (IU/mL)/anti‑HBs
1 F/57 30 02/23/2017 06/05/2017 Positive/< 10.0
2 M/65 30 11/21/2016 07/31/2017 Positive/< 10.0
3 M/54 4 06/26/2017 11/10/2017 Positive/< 10.0
4 M/41 22 07/23/2017 10/13/2017 Positive (5.66)/< 10.0
5 M/37 32 10/16/2017 10/18/2017 Positive (2661.34)/< 10.0
6 F/61 11 10/01/2014 10/30/2017 Positive (2985.25)/< 10.0
7 F/79 17 09/30/2010 10/31/2017 Positive (7305.00)/< 10.0
8 F/63 29 09/16/2011 11/07/2017 Positive (2960.00)/< 10.0
9 F/63 32 09/16/2011 11/07/2017 Positive (2960.00)/< 10.0
10 M/72 12 07/18/2016 11/07/2017 Positive (757.59)/< 10.0
11 F/34 15 11/13/2017 11/13/2017 Positive (5396.97)/< 10.0
12 F/34 17 01/08/2018 01/22/2018 Positive (1447.57)/< 10.0
13 M/29 17 01/05/2018 01/24/2018 Positive (2679.36)/< 10.0
14 M/29 32 01/05/2018 01/24/2018 Positive (2679.36)/< 10.0
15 M/69 30 02/26/2018 03/20/2018 Positive (4784.05)/< 10.0
16 M/35 16 03/05/2018 03/20/2018 Positive (3544.88)/< 10.0
17 F/63 2 01/18/2000 11/28/2017 Positive (4780.80)/< 10.0
18 F/63 31 01/18/2000 11/28/2017 Positive (4780.80)/< 10.0
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sample. The mixture was gently agitated at 37 °C for 2 h 
and then centrifuged (13,000  rpm, 5  min). Following 
this, the supernatant was discarded and 400 µL of Solu-
tion C and 50 µL Proteinase K (20 mg/mL) were added 
to the sample. The mixture was incubated at 56 °C with 
gentle agitation for 3 h (Additional file 1).
The DNA solution from each sample was puri-
fied using a QIAamp DNA Investigator Kit (Qiagen, 
Hilden, Germany).  The DNA samples were then puri-
fied using a silica membrane following the manufactur-
er’s instructions and as detailed in the Additional file 1. 
The purified DNA was eluted in 100 µL of Buffer ATE 
(Additional file 1).
Quantitative polymerase chain reaction
Quantitative real-time PCR (qPCR) was performed using 
a 7900HT Fast Real-Time PCR System (Applied Biosys-
tems, Foster city, CA, USA) and a Hepatitis B Virus PCR 
Kit (MyBiosource, Inc., San Diego, CA, USA) with oasig 
lyophilized 2× qPCR Mastermix (Primerdesign, Ltd., 
Camberley, UK). The PCR reactions were set up accord-
ing to the manufacturer’s instructions by aliquoting 15 μL 
of master mix into each reaction well of a 96-well reac-
tion plate (Applied Biosystems, Foster city, CA, USA) 
followed by 5 μL of each experimental DNA sample for 
a final volume of 20 μL per reaction. Primer details are 
included in Additional file 1. Six concentrations of a ref-
erence DNA sample (the ‘Standard DNA’) were prepared 
by serial dilution and analyzed in triplicate for each 
96-well plate in the study. All experimental DNA samples 
were assayed in triplicate. The thermal cycling profile 
included Stage 1: 2 min at 95 °C; Stage 2: 50 cycles of 10 s 
at 95 °C and 60 s at 60 °C with signal acquisition (Addi-
tional file 1).
Data and statistical analysis
The data were analyzed with the real-time PCR thermal 
cycler software (SDS 2.4.1 for the 7900HT). Fluorescence 
data were normalized to the ROX signal and the baseline 
signal and threshold were set automatically. The HBV 
DNA copy number in the fresh dentin was compared 
with that in the processed dentin of same tooth. Cut off 
levels and specificity were not determined due to the lim-
ited number of human dentin samples.
All statistical analysis was performed using R Statisti-
cal Software (version 3.5.1; R Foundation for Statistical 
Computing, Vienna, Austria). Mann–Whitney U test 
was used to compare numerical measurements between 
groups and differences were considered statistically sig-
nificant for P-values were less than 0.05.
Results
HBV DNA in fresh dentin
Among the eighteen  dentins obtained from HBV-
infected patients, ten fresh dentin  specimens (55.6%) 
contained HBV DNA. HBV DNA in the other eight fresh 
dentins (44.4%) was not detected owing to insufficient 
DNA amounts or quality needed for analysis (Fig.  2). 
Linear regression analysis (univariate) of the correlation 
between HBV copy number in the fresh dentin and the 
HBsAg positivity based on patient serology was not sta-
tistically significant (P = 0.3536).
HBV DNA in processed dentin
HBV DNA in eight of the ten fresh dentin samples 
(80%) that were positive for HBV DNA appeared to be 
Fig. 1 Experimental design flow diagram. Preparation of fresh 
dentin (control group) and processed dentin (experimental group) 
for measurement of hepatitis B virus (HBV) DNA. The teeth from 
chronically-infected HBV patients were severe at the cemento–
enamel junction. a A segment of root (control group) cleaned of 
soft and hard tissues was used as fresh dentin to measure levels of 
HBV DNA. b Other segment of root (experimental group) was used 
as processed dentin particles to measure levels of HBV DNA. The 
HBV DNA of fresh dentin (control group) measured as copy number 
by quantitative polymerase chain reaction was compared that of 
processed dentin (experimental group)
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completely degraded or eliminated by the DDM pro-
cessing. Samples from two of the ten patients (20%) 
whose fresh dentin were positive for HBV DNA were 
extensively degraded after processing (#3 and #14). The 
difference between the fresh dentin and processed den-
tin with respect to HBV DNA-positivity was confirmed 
by multivariable logistic regression analysis with a P 
value = 0.0167 confirming the statistical significance.
HBV DNA copy numbers of 1.79 and 4.03 in the pro-
cessed dentin of patients 3 and 14, respectively, cor-
responded with the highest and second highest copy 
numbers (85.42 and 34.4, respectively) in the fresh dentin 
samples, which demonstrated that the samples under-
went extensive degradation during the DDM process-
ing. The eight fresh dentin samples with HBV DNA copy 
numbers less than 31.9 were all negative in their corre-
sponding processed dentin samples and were considered 
as complete inactivation or elimination of HBV (Fig.  3, 
Additional file 2).
Discussion
The purpose of the current study was to evaluate the abil-
ity of a processing procedure for the generation of DDM 
to inactivate or eliminate HBV in dentin obtained from 
chronically infected patients by comparing the HBV 
DNA levels in processed dentin with those in fresh den-
tin. It was our hypothesis that the processing procedure 
would degrade nucleic acids, inactivating HBV and ren-
dering it noninfectious. The viral burden in fresh dentin 
might be a primary factor for determining the processing 
method to prevent HBV transmission since the removal 
of HBV DNA in processed dentin might assure the safety 
for the allogenic application of dentin. Validation of viral 
inactivation by the processing procedure could lead to 
the expanded application of allogenic DDM in the dental 
field.
Based on the results of the current study, dentin may 
be a potential carrier of HBV since 55.6% (10/18) of the 
fresh dentin samples that were stored refrigerated with-
out removal of blood, saliva, or other foreign bodies at 
the dental clinic tested positive for HBV DNA by qPCR.
Eight of the processed dentin samples among the ten 
HBV DNA-positive fresh dentin samples (80%) showed 
complete degradation of nucleic acid of HBV DNA with 
the reduction being statistically significant. HBV DNA 
persisted in two of the processed dentin samples among 
the ten HBV DNA-positive fresh dentin samples (20%). 
These two corresponded with the fresh dentin samples 
containing the highest and second highest copy number 
of HBV DNA 85.42 and 34.4 compared to 1.79 and 4.03, 
respectively, post processing. A copy number less than 
10 is generally considered to be negative for virus even 
though the actual cut off levels and specificity were not 
determined in the current experiment.
There have been several approaches used beyond 
standard donor testing and screening procedures in the 
developmental history of bone banks to prevent viral 
transmission. The use of  H2O2 as an oxidizing chemical 
is used to process bone allografts in effort to eradicate 
microorganisms and viruses. Viral clearance following a 
1 h  H2O2 treatment verifies that the risk for disease trans-
mission can be greatly reduced or eliminated by greater 
than six logs sterility assurance level (SAL), except for the 
porcine parvovirus (PPV) virus [11]. SAL is the probabil-
ity that an item will not be sterile after it has been sub-
jected to a validated sterilization process. With a SAL of 
 10−6, the odds of an organisms surviving after allograft 
processing are less than one in one million [5]. Processed 
bone allografts obtained from an HIV-infected donor 
and cleaned with a 30% ethanol solution and rinsed in 
100% ethanol prior to lyophilization failed to transmit 
the virus to the graft recipient, whereas unprocessed 
bone allografts obtained from the same donor transmit-
ted the virus [12]. Proprietary solutions, including those 
used for chemical sterilization with ethylene oxide, may 
contain particular bactericidal, viricidal, and fungicidal 
agents but there is no industry-wide standard for their 
Fig. 2 Number of dentin samples from serologically hepatitis B 
virus (HBV)-positive patients, the number of HBV DNA-positive fresh 
dentin samples, and the number of HBV DNA-positive processed 
dentin samples. Among eighteen dentins from HBV-infected patients, 
ten fresh dentin samples (55.6%) contained detectable HBV DNA. 
HBV DNA of the other eight fresh dentins (44.4%) was considered 
degraded or insufficient levels of DNA available for detection. No 
significant difference was observed between the serologically 
positive dentin and HBV DNA-positive fresh dentin (P = 0.3536) based 
on linear regression analysis (univariate) of the relationship. HBV DNA 
from eight of the ten fresh dentin samples (80%) that were positive 
for HBV DNA appeared degraded or eliminated by the processing. 
Two (patients #3 and #14) of the ten fresh dentin samples that were 
positive HBV DNA (20%) were extensively degraded after processing
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use [13].  Freeze-drying is a process by which water is 
removed from the tissue to the point where cellular activ-
ity is no longer supported, which may inactivate HIV 
and HCV and reduce the risk of transmission by infected 
blood products and bone marrow [14].
Although the processing of dentin employs steps of 
washing, defatting, demineralization, freeze-drying, and 
sterilization with ethylene oxide gas, the majority of 
studies on viral clearance has been focused on the dem-
ineralization process in relation to the development of 
demineralized freeze-dried bone allograft  (DFDBA). In 
the processing of preparing DFDBA, investigators have 
demonstrated that exposing allografts to low-pH solu-
tions such as hydrochloric acid inactivates numerous 
viruses, including HIV, HBV, HCV, cytomegalovirus, and 
poliovirus [15–17]. Scarborough et al. performed a study 
to validate the effectiveness of a bone demineralization 
process with respect to its inactivation of viruses, includ-
ing HIV, duck hepatitis B virus (a model for human hepa-
titis B), bovine viral diarrheal virus (a model for human 
hepatitis C), human cytomegalovirus, and human polio-
virus  (a model for small non-enveloped viruses such as 
hepatitis A). The infectivity of all RNA and DNA viruses 
is reduced more than one-million-fold  (10−6) for all the 
viruses tested and as much as one-trillion-fold  (10−12) for 
poliovirus. For example, the probability of HIV survival 
after bone demineralization is less than 1 in 2.8 billion 
[15, 17].  The demineralization method degrades nucleic 
acids in retrovirus-infected cortical bone and thereby 
preventing disease transmission through the allotrans-
plantation of DBM powder. The ability of a deminer-
alization procedure to effectively inactivate an infectious 
retrovirus in systemically infected bone while maintain-
ing the desired osteoinductive  properties of powdered 
DBM appears to provide an additional margin of safety 
while sustaining optimal allograft efficacy [18].
The Centers for Disease Control and Prevention (CDC) 
report that DFDBA materials are widely used in perio-
dontal and dental therapy and that there are no reports of 
disease transmission during the 30-year history of using 
freeze-dried bone allografts [19]. There has also been no 
report of disease transmission (HIV or hepatitis viruses) 
using demineralized bone products  (FDBA, DFDBA, 
DBM) [20].
DDM consists of osteoconductive  type 1 collagen 
and noncollagenous proteins, including osteoinductive 
bone morphogenetic proteins (BMPs), which stimulate 
the formation of bone at a defect site similar to that 
treated with DBM that is washed, demineralized with 
organic solvents, freeze-dried, and sterilized, resulting 
Fig. 3 Change in copy number of hepatitis B virus (HBV) DNA from fresh dentin to processed dentin. Copy numbers of 1.79 and 4.03 in two 
processed dentin samples (patients 3 and 14) corresponded with the fresh dentin samples containing the highest (a) and second highest (b) 
copy numbers (85.42 and 34.4, respectively) of HBV DNA were considered extensively degraded. Eight fresh dentin samples with HBV DNA copy 
numbers less than 31.9 were negative for HBV DNA in the processed dentin and considered to be completely degraded (inactivation or elimination 
of HBV). A copy number less than 10 is generally considered negative for virus, even though the cut off levels were not determined in the current 
experiment. With P < 0.05 being considered statistically significant, the correlation of copy number between fresh dentin and processed dentin was 
confirmed by multivariable logistic regression and determined to be statically significant (P = 0.0167)
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in a significant level of viral inactivation as previously 
mentioned [1, 21]. The major differences between DDM 
and DBM are that bone contains viable osteocytes 
and blood vessels (harversian canals and endothelial 
cells) while there are no cells or blood vessels in den-
tin that could be a potential source of transmissible 
viruses [22].  Tissues obtained from living donors have 
lower rates of bacterial contamination than tissues har-
vested from cadavers at autopsy [23]. Likewise, because 
dentins are obtained from patients during dental treat-
ment, the possibility of disease transmission from den-
tin might be lower than that from a bone allograft. For 
the described reasons, a dentin allograft might be safer 
than a bone allograft.
However, while we measured HBV DNA levels in 
processed dentin, the precise step of washing, defat-
ting, demineralization, or freeze-drying that resulted in 
the degradation of the virus, either alone or in combi-
nation, was not determined. Therefore, more studies to 
determine the effects of the various steps of dentin pro-
cessing on the degradation of HBV and other viruses 
are warranted.
Of note, we currently do not know whether or not the 
positive HBV DNA in processed dentin was infectious 
since we did not determine the cutoff levels of HBV 
DNA in this experiment. Since qPCR techniques may 
amplify a small segment of degraded HBV DNA in the 
absence of intact virus, additional studies are neces-
sary to determine whether the detected HBV DNA that 
remained in the processed dentin samples correlates 
with infectious virus. Finally, the established validation 
of viral inactivation procedures, including the harvest-
ing of tissue in a sterile manner, repeated washings, 
immersion in ethanol, freeze-drying, demineralization, 
and sterilization, should be confirmed for rendering a 
safe DDM allograft [24, 25].
Conclusions
The results of the current study suggested that the posi-
tive detection of HBV DNA in 10 (55.6%) fresh dentin 
samples may be indicative of infected dentin, which may 
serve as potential carriers of HBV. A  processing proce-
dure for producing DDM completely degraded the HBV 
DNA in eight of the ten fresh dentin that were positive 
for HBV DNA. This reduction was statistically signifi-
cant. The two processed dentin samples with extensively 
degraded HBV DNA that remained positive need to be 
evaluated for infectivity. For the purpose of achieving 
completely virus-free grafting specimens, additional 
studies are necessary, including those to validate viral 
inactivation to determine whether or not the processed 
dentin samples that were positive for HBV DNA were 
infectious. The ability of the processing procedure for 
DDM to effectively inactivate HBV in specimens from 
infected patients appears to provide an expanded mar-
gin of safety for the clinical application of allogenic DDM 
from the bench to chairside.
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